Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Xenon Pharmaceuticals

NASDAQ XENE
$40.34 0.0000 0.0000%
Today share price
Canada
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 17 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

3.13B
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
2.98B
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
1.40
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
77.59M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-12.42 %

Upcoming events Xenon Pharmaceuticals

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Xenon Pharmaceuticals

Stock analysis Xenon Pharmaceuticals

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-16.60 28.62
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.
3.37 4.29
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-13.54 9.93
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
0.67 0.65
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-21.25 7.67

Price change Xenon Pharmaceuticals per year

9.32$ 33.72$
Min Max

Summary analysis Xenon Pharmaceuticals

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Xenon Pharmaceuticals

Revenue and net income Xenon Pharmaceuticals

All parameters

Stock news Xenon Pharmaceuticals

All news
27 November 2023 в 16:35

Xenon Pharmaceuticals’ stock falls as depression treatment has mixed results in clinical trial

21 July 2022 в 15:45

Xenon Pharmaceuticals started at overweight with $55 stock price target at J.P. Morgan

23 June 2022 в 13:17

Xenon Pharmaceuticals Shares Slip Premarket After Stock Offering >XENE

23 June 2022 в 13:10

Xenon Pharmaceuticals Shares Slip Premarket After Stock Offering >XENE

21 June 2022 в 20:51

Xenon Pharmaceuticals Shares Rise 9% After Positive FDA Meeting

21 June 2022 в 20:51

Xenon Pharmaceuticals Shares Rise 9% After Positive FDA Meeting

6 October 2021 в 19:35

Xenon Pharmaceuticals Shares Rise 10% After Public Offering Prices

6 October 2021 в 19:35

Xenon Pharmaceuticals Shares Rise 10% After Public Offering Prices

4 October 2021 в 14:25

Xenon Pharmaceuticals Reports Positive Phase 2b Result for Epilepsy Drug

4 October 2021 в 14:25

Xenon Pharmaceuticals Reports Positive Phase 2b Result for Epilepsy Drug

About company Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel modulator that is Phase III clinical trials for the treatment of KCNQ2 epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop FX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.
Address:
200-3650 Gilmore Way, Burnaby, BC, Canada, V5G 4W8
Company name: Xenon Pharmaceuticals
Issuer ticker: XENE
ISIN: CA98420N1050
Country: Canada
Exchange: NASDAQ
Currency: $
IPO date: 2014-11-05
Sector: Healthcare
Industry: Biotechnology
Site: https://www.xenon-pharma.com

On which stock exchange are Xenon Pharmaceuticals (XENE) stocks traded?

Xenon Pharmaceuticals (XENE) stocks are traded on NASDAQ.

What is the ticker of Xenon Pharmaceuticals stocks (XENE)?

The stock ticker of Xenon Pharmaceuticals’s stocks or in other words, the code is XENE. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Xenon Pharmaceuticals (XENE) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Xenon Pharmaceuticals (XENE) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are Xenon Pharmaceuticals (XENE) stocks traded?

Xenon Pharmaceuticals (XENE) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Xenon Pharmaceuticals (XENE) stocks today?

The current price of Xenon Pharmaceuticals stocks on 17.05.2024 is 40.34 dollars. per share.

What is the dynamics of Xenon Pharmaceuticals (XENE) stocks from the beginning of the year?

Xenon Pharmaceuticals (XENE) quotes have increased by -10.18% from the beginning of the year up to 40.34 dollars. per 1 stocks.

How much did Xenon Pharmaceuticals (XENE) stocks increase in мае 2024?

This month Xenon Pharmaceuticals (XENE) quotes have increased by -5.06% to 40.34 dollars. per share.

How much are Xenon Pharmaceuticals (XENE) stocks worth?

Today, on October, 17.05.2024 Xenon Pharmaceuticals’s (XENE) stocks cost 40.34 dollars..

What is the market capitalization of Xenon Pharmaceuticals (XENE)?

Capitalization is the market value of Xenon Pharmaceuticals (XENE) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 17.05.2024, the market capitalization of Xenon Pharmaceuticals (XENE) is estimated at about 3130166124 dollars.